3 Branded Generics Marketer, Cardiovascular and CNS Leader and Paracetamol and Metformin Ingredients Maker Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India
- October 26, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India: ROE of 11.7% to 25.5% and FY22 to FY26 revenue CAGR of 9.2% to 12.4%. Prices as of 23 Oct 2026.
Quick Answer
The three branded generics and API pharma stocks to watch are Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India. Their return on equity ranges from 11.7% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 12.4%. Torrent Pharmaceuticals leads on both return on equity at 25.5% and revenue growth at 12.4% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Branded generics and API pharma stocks let investors follow companies that serve a growing part of the Indian economy. Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India cover a branded generics marketer, a cardiovascular and central nervous system leader and a paracetamol and metformin ingredients maker.
This list covers three branded generics and API pharma stocks with complete current figures: Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Generics and API Pharma Stocks?
Branded generics and API pharma stocks are listed drug makers that sell branded generics, prescription brands and high-volume active ingredients in India and overseas. Their earnings depend on brand strength, launches, plant quality and export demand.
Branded Generics and API Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 1,770.4 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
| Torrent Pharmaceuticals | 4,524.4 | 173,079 | 80.3 | 36.0 | 25.5 | 1.79 |
| Granules India | 794.75 | 22,002 | 33.2 | 36.0 | 11.7 | 0.30 |
On valuation, Emcure Pharmaceuticals and Granules India trade at a P/E below the industry P/E, while Torrent Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing branded generics and API pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in branded generics and API pharma stocks can use the coming numbers to test whether growth is holding.
Why Do Branded Generics and API Pharma Stocks Have a Strong Roadmap in India?
Branded generics and API pharma stocks have a strong roadmap in India because growing healthcare access and chronic therapy use lift brand demand, while global buyers add dependable ingredient suppliers.
- Brand marketing. Strong doctor networks help brands scale.
- Chronic therapies. Long-term treatments give repeat demand.
- Ingredient volumes. High-volume molecules support steady output.
Why Emcure Pharmaceuticals Features Among These Branded Generics and API Pharma Stocks
Among the branded generics and API pharma stocks on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.
In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Why Torrent Pharmaceuticals Features Among These Branded Generics and API Pharma Stocks
Among the Zuventus and Avet brand shares on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.
In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%.
Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.
Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.
Why Granules India Features Among These Branded Generics and API Pharma Stocks
Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.
Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore.
Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What to watch: Monitor new product approvals and the share of finished dosages in total sales.
Emcure Pharmaceuticals vs Torrent Pharmaceuticals vs Granules India on Key Financials
The table below sets the three branded generics and API pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
| Torrent Pharmaceuticals | 8,705 | 13,886 | 12.4% | 2,138 | 15.4% |
| Granules India | 3,783 | 5,386 | 9.2% | 595 | 11.0% |
Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Torrent Pharmaceuticals combines the largest FY26 revenue at Rs 13,886 crore with the fastest revenue growth, a 12.4% compound annual rate. A useful habit with branded generics and API pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Emcure Pharmaceuticals | 2,104 | 2,583 | 22.7% |
| Torrent Pharmaceuticals | 3,141 | 4,909 | 56.3% |
| Granules India | 1,226 | 1,479 | 20.6% |
Key Risks to Check Before Investing in Branded Generics and API Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these branded generics and API pharma stocks, the main points are: Long-term Zuventus and Avet brand shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices can fall in some markets.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter branded generics and API pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Branded Generics and API Pharma Stocks
Branded generics and API pharma stocks reward investors who follow demand trends, order books and margins together. Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India each have a clear plan to grow. Based on the 23 October 2026 close, Emcure Pharmaceuticals trades at Rs 1,770.4, Torrent Pharmaceuticals at Rs 4,524.4 and Granules India at Rs 794.75. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these branded generics and API pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track branded generics and API pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are branded generics and API pharma stocks?
Ans. Branded generics and API pharma stocks are listed drug makers that sell branded generics, prescription brands and high-volume active ingredients in India and overseas. Their earnings depend on brand strength, launches, plant quality and export demand. This list looks at three of them, Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which branded generics and API pharma stocks are covered in this list?
Ans. This list covers Emcure Pharmaceuticals, Torrent Pharmaceuticals and Granules India. Based on the 23 October 2026 close, Emcure Pharmaceuticals traded at Rs 1,770.4, Torrent Pharmaceuticals at Rs 4,524.4 and Granules India at Rs 794.75. Their return on equity ranges from 11.7% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 12.4%.
Why do branded generics and API pharma stocks have a strong future roadmap in India?
Ans. Branded generics and API pharma stocks have a strong roadmap in India because growing healthcare access and chronic therapy use lift brand demand, while global buyers add dependable ingredient suppliers. The main drivers are as follows. Brand marketing. Strong doctor networks help brands scale. Chronic therapies. Long-term treatments give repeat demand. Ingredient volumes. High-volume molecules support steady output. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
How has Torrent Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
How has Granules India performed financially?
Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What risks should investors check before buying branded generics and API pharma stocks?
Ans. Investors should check a few risks before buying branded generics and API pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices can fall in some markets. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of branded generics and API pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.